The company has a promising pipeline with XP-8121, a once-weekly levothyroxine injection for hypothyroidism, showing positive phase 2 data. Despite a decline in Keveyis revenue, Xeris remains a ...

Kristen Fischer has written for numerous health publications, hospitals, and medical companies, and is a member of the Association of Health Care Journalists. Levothyroxine, a common medication ...

Levothyroxine, a cornerstone in treating hypothyroidism, has come under scrutiny as emerging evidence suggests its impact on bone health may be more significant than previously understood ...

Could Synthroid be doing more harm than good? New research links the thyroid medicine to potential bone loss. Dr. Yadal Safai says the study was “quite small” and that “much more research ...

Levothyroxine — marketed under brand names such as Synthroid — is the second-most commonly prescribed medication among older adults in the US. It’s consumed by about 7% of the US population.

The dosage can vary depending on what condition the drug is used to treat. Levothyroxine intravenous (IV) injection is approved by the FDA to treat myxedema coma (a severe form of hypothyroidism ...

Long-acting, injectable medication is seen as a big advance in HIV prevention (PrEP) and treatment — an effective alternative to taking pills daily. Still no vaccine for HIV, but long-active ...

XP-8121 employs the Company’s XeriSol™ formulation technology to enable a novel once-weekly SC injection of levothyroxine. This novel formulation significantly increases the bioavailability of ...